Samuel Bakhoum Appointed Chief Scientific Officer at Volastra Therapeutics
Slice of Healthcare Team
Oct 18, 2024
Key Highlights
- Samuel Bakhoum, co-founder, named Chief Scientific Officer at Volastra Therapeutics.
- Dr. Bakhoum joins from Memorial Sloan Kettering, known for expertise in chromosomal instability.
- His appointment strengthens Volastra’s clinical leadership and innovative cancer therapies.
Source: Business Wire
Notable Quotes
“ We are incredibly excited to welcome Sam to the Volastra team at such a pivotal moment in the company’s growth. ”
Charles Hugh-Jones, M.D., FRCP, Chief Executive Officer at Volastra
“ I am thrilled to join Volastra’s leadership as it advances the field in discovering therapies targeting chromosomal instability. ”
Samuel Bakhoum, M.D., Ph.D., Chief Scientific Officer at Volastra
“ His scientific acumen and innovative thinking around cancer research will add greatly to our capabilities. ”
Sandi Peterson, Chair of the Board at Volastra
